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Table: 809P Multivariable Cox-Regression OS Analysis
Variable HR (95%CI) p-value
Statin Use 0.79 (0.62-0.99) 0.048
Treatment Arm 0.66 (0.55-0.79) < 0.001
Baseline PSA 1 (1-1) 0.394
Baseline Hb 0.89 (0.85-0.93) < 0.001
Baseline ALP 1 (1-1) 0.009
Visceral Metastases 1.36 (1.11-1.68) 0.003
ECOG PS 1.67 (1.43-1.96) < 0.001
Conclusions:Use of statins by pts treated in the TROPIC trial was associated with a
longer OS, independent of treatment arm and other prognostic variables. Further anal-
yses will elucidate the role of statins in mCRPC.
Clinical trial identification: EudraCT: 2006-003087-59; NCT00417079.
Legal entity responsible for the study:David Lorente / Prostate Targeted Therapy
Group.
Funding: The TROPIC trial was funded by Sanofi Aventis. No specific funding was
received for the development of the current abstract.
Disclosure: All authors have declared no conflicts of interest.
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Background: The value of continuation of luteinizing hormone-releasing hormone
(LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial
and clear evidence is lacking. Especially upon treatment with the life-prolonging cyto-
chrome P450 17-alpha-hydroxylase/C17,20 lyase (Cyp17)-inhibitor, abiraterone, which
in combination with prednisone, has the ability to further suppress testosterone serum
levels over LHRH therapy alone, continuation of LHRH therapy seems to be negligible.
The aim of the SPARE trial therefore was to explore the role of continuation of LHRH
therapy when starting treatment with abiraterone acetate plus prednisone (AAþP) in
patients with asymptomatic or mildly symptomatic, chemotherapy-naı¨ve CPRC.
Methods: Patients were randomized to receive continuing LHRH therapy versus
LHRHwithdrawal at the time of starting abiraterone AAþP therapy (NCT02077634).
The primary endpoint was rate of rPFS at month 12. Secondary endpoints included
PSA response rate, objective response, time to PSA progression and safety.
Results:Altogether, 68 patients were randomized. Median age was 75 (60-86) years
with amedian PSA at baseline of 23.9 (0.17-1680) ng/ml. Results of the secondary end-
points were evaluated.
Table: 810P
LHRHþAAþP AAþP HR (p-value)
Patients (n) 34 33
Median age (range) 74 (60-86) years 76 (60-86) years
Median baseline PSA
(range)
31.9 (0.17-313.2)
ng/ml
20.59 (1.97-1680)
ng/ml
PSA-decline 50% 23/34 (67.6%) 24/33 (72.7%)
Median treatment
duration (d)
266 420 1.667 (0.197)*
Time to PSA
progression (d)
288 336 1.733 (0.188)*
*study was not powered for these endpoints.
Conclusions: The results of the exploratory study show that AAþ P without continua-
tion of LHRH therapy leads to considerable PSA response rates and longer time to PSA
progression. The currently assessed efficacy is comparable to the results of the COU-
AA-302 trial, hypothesising that continuation of LHRH therapy may not be necessary
upon treatment with AAþ P. Results on the primary endpoint and the safety profile
are pending and are currently being evaluated.
Clinical trial identification:NCT02077634.
Legal entity responsible for the study: Saarland University.
Funding: Janssen-Cilag.
Disclosure: C. Ohlmann: Research funding: Janssen-Cilag. All other authors have
declared no conflicts of interest.
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Background: Subset analysis of trials investigating taxanes in patients with mCRPC
suggest an association between Grade3NP and disease outcomes. In the Phase 3
PROSELICA trial (NCT01308580), NP was more common in patients receiving cabazi-
taxel 25mg/m2 (C25) vs cabazitaxel 20mg/m2 (C20) - 73% vs 42%, respectively. Post
hoc analyses of PROSELICA examined the relationship between incidence of NP, sur-
vival and response.
Methods: PROSELICA assessed the non-inferiority of C20 (n¼ 598) vs C25 (n¼ 602)
in terms of overall survival (OS) in men with mCRPC. Prophylactic granulocyte col-
ony-stimulating factor was given to patients with Grade3NP. OS and progression-
free survival (PFS) were analyzed using Kaplan-Meier (KM) estimates and Cox propor-
tional hazard models. Nominal p values were determined by log-rank tests. Prostate-
specific antigen response rate (PSArr; defined as proportion of patients with a> 50%
PSA decline from baseline) was analyzed in the eligible population using KM estimates
with Chi2 tests and odds ratios. OS, PFS and PSArr were correlated with Grade3NP
occurrence and baseline neutrophilia (neutrophils7000G/l) by univariate analysis.
Results: In the intent-to-treat (ITT) population, development of Grade3NP was
associated with better PSArr, PFS and OS (p< 0.001; Table). The positive association
was observed in both treatment arms and in poor-risk patients with baseline
neutrophilia.
Table: 811P
Population Outcome Grade
3NP
No Grade
3NP
Hazard
ratio/Odds
ratio
p value
ITT population
(n¼ 1200)
OS, months (mo) 15.1 12.4 0.78 0.0002
PFS, mo 3.7 2.8 0.79 0.0001
PSArr, % n¼ 1079 44.1 25.5 2.3 <0.0001
C25 (n¼ 602) OS, mo 15.3 12.2 0.77 0.009
PFS, mo 3.5 3.5 0.84 0.07
PSArr, % n¼ 538 46.2 34.5 1.6 0.015
C20 (n¼ 598) OS, mo 14.6 12.6 0.78 0.006
PFS, mo 4.2 2.3 0.75 0.0008
PSArr, % n¼ 541 40.7 21.3 2.5 <0.0001
Neutrophilia
(n¼ 174)
OS, mo 12.8 7.5 0.63 0.004
PFS, mo 4.1 2.1 0.66 0.008
PSArr, % n¼ 156 43.8 16.9 3.8 0.0002
Conclusions: Post hoc assessment of Grade3NP in PROSELICA was associated with
improved survival and response to cabazitaxel independent of dose. These results are
consistent with data obtained in the Phase 3 TAX327 (docetaxel) and TROPIC (cabazi-
taxel) trials. Funded by Sanofi.
Clinical trial identification:NCT01308580.
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Background: PROSELICA (NCT01308580) assessed the non-inferiority of cabazitaxel
20mg/m2 (C20) vs 25mg/m2 (C25) in patients (pts) with mCRPC post docetaxel, while
FIRSTANA (NCT01308567) investigated whether C20 and C25 were superior to doce-
taxel 75mg/m2 (D75) in chemotherapy-naive mCRPC. This analysis evaluated the
impact of cabazitaxel on HRQL in both trials.
Methods: Alongside pain and analgesic score, HRQLwas assessed using the Functional
Assessment of Cancer Therapy Prostate (FACT-P) questionnaire. The analysis focused
on FACT-P (clinically meaningful improvement or deterioration of total score [TS])
among responders.
Results: Pt baseline characteristics are shown in the table. In PROSELICA, 57.2% and
59.4% of pts receiving C20 and C25 had FACT-P TS improvements; in FIRSTANA,
63.5%, 62.3% and 57.7% of pts receiving C20, C25 and D75 had FACT-P TS improve-
ments. In FACT-P responders, FACT-P TS improvements occurred as early as Cycle
(C) 1 (mean change from baseline: PROSELICA C20 10.4, n¼ 264; C25 10.6, n¼ 266;
FIRSTANA C20 11.7, n¼ 206; C25 11.7, n¼ 202; D75 9.0, n¼ 195); these were largely
maintained. For pts with a pain response in PROSELICA, FACT-P TS improvements
occurred as early as C1 (C20 6.8, n¼ 71; C25 11.1, n¼ 81) and were maintained until
C8 (C20 10.6, n¼ 43; C25 9.6, n¼ 44). In FIRSTANA, FACT-P TS improvements in
pts with a pain response were seen as early as C1 or C2 (C1: C20 15.5, n¼ 41; C25 12.5,
n¼ 41; D75, 7.9, n¼ 32) andmaintained until C9 (C20 9.0, n¼ 27; C25 10.5, n¼ 26;
D75 16.4, n¼ 20). In pts with a tumor or PSA response, HRQLwas maintained for all
treatment arms in both studies. Additional results for clinical responder subgroups and
FACT-P subscales will be presented.
Conclusions:More than half of the pts experienced HRQL improvements, which were
maintained. Pts with a pain response experienced HRQL improvements. Funding:
Sanofi.
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Background: The usual sequence of progression events in mCRPC patients treated
with new hormonal agents is known: PSA progression, followed by radiological pro-
gression and finally pain progression (Ryan, NEJM 2013; Beer, NEJM 2014). Although
pain was associated with poor overall survival (OS) in the TAX 327 (Berthold, Clin
Cancer Res 2008) and CALGB trials (Halabi, JCO 2008), the influence of type of pro-
gression on outcomes is not well documented in phase III trials with chemotherapy.
Here, we investigated the impact of type of progression on OS inmCRPC patients
receiving docetaxel-based chemotherapy.
Methods:Data from the phase III study VENICE evaluating docetaxel 75mg/m2 q3w6
aflibercept (Tannock, Lancet Oncol 2013) was used as a training dataset. At randomiza-
tion, group 1 (G1) had PSA progression only (n¼ 231), G2 had radiological progres-
sion (6 PSA) but no pain (n¼ 348), and G3 had pain (6 PSA,6 radiological)
(n¼ 447). The TAX327 definition for pain was used: Mean present pain intensity 2
and/or mean analgesic score 10 within 7 days prior to randomization (Tannock,
NEJM 2004). The impact of type of progression on OS was evaluated in a multivariate
Cox regression analysis with backward elimination (5% level), stratified for ECOG per-
formance status (0-1 vs 2) and treatment arm.
Results: In the VENICE trial median OS was 28.6 months for G1, 26.3 months for G2
and 16.9 months for G3. Hazard ratios [95%CI] for death were 1.14 [0.92-1.41] in G2
Table: 812P
Baseline characteristics FIRSTANA PROSELICA
D75 (n¼ 391) C20 (n¼ 389) C25 (n¼ 388) C20 (n¼ 598) C25 (n¼ 602)
Median age, years (range) 69.0 (41–87) 68.0 (44–90) 68.5 (42–85) 68.0 (45–89) 69.0 (45–88)
ECOG PS, n (%)
0–1 374 (95.7) 370 (95.1) 376 (96.9) 539 (90.1) 540 (89.7)
2 17 (4.3) 19 (4.9) 12 (3.1) 59 (9.9) 62 (10.3)
Mean PSA, ng/mL (SD) 252.8 (625.2) 213.2 (434.2) 257.9 (578.8) 451.5 (881.0) 444.0 (834.0)
Median present pain intensity, score (range) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–5.0) 2.0 (0.0–5.0)
Median FACT-P TS (range) 107.4 (41.1–152.0) 107.1 (47.2–151.0) 105.7 (40.1–148.8) 102.8 (37.0–152.8) 101.6 (33.9–150.9)
C20, cabazitaxel 20mg/m2; C25, cabazitaxel 25mg/m2; D75, docetaxel 75mg/m2; ECOG PS, Eastern Cooperative Oncology Group Performance Status;
FACT-P TS, Functional Assessment of Cancer Therapy Prostate Total Score; PSA, prostate-specific antigen; SD, standard deviation.
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